Quick answer
Finasteride and Tadalafil can both appear in BPH treatment strategy plans, but they are not interchangeable. One approach is designed around prostate biology; the other is often chosen when urinary urinary problems coexist with erectile dysfunction. The better fit depends on prostate enlargement, erectile function, PSA monitoring, onset expectations and sexual trade-offs.
What this page helps you decide
- Prostate shrinkage versus symptom-plus-erection treatment strategy
- Side-by-side therapy decision table
- When erectile function changes the BPH comparison
Evidence used on this page: NIDDK: Enlarged Prostate (BPH) · DailyMed drug labeling · American Urological Association: BPH guidance
Useful next reads: Finasteride guide · Tadalafil guide · Compare BPH medications
Prostate shrinkage versus symptom-plus-erection treatment strategy
Finasteride is a 5-alpha-reductase inhibitor and reduces conversion to DHT and can reduce prostate volume over time. Tadalafil is a PDE5 inhibitor and can improve lower urinary tract urinary problems and can also treat erectile dysfunction. The key difference is whether the treatment strategy therapy decision is centered on urinary mechanics, prostate growth, erectile function, or some combination of those goals.
Finasteride works more slowly than an alpha blocker and is aimed at longer-horizon control in appropriately enlarged prostates; Tadalafil is considered when urinary urinary problems and erectile function are both part of the therapy decision. Blood-pressure and interaction screening also differs. Usually is not chosen for blood-pressure effects; vasodilatory effects and interactions, especially with nitrates, are useful to weigh.
This is why a man with bothersome BPH plus erectile dysfunction may have a different therapy decision tree from someone whose main concern is progressive enlargement or rapid improvement in flow urinary problems.
Side-by-side therapy decision table
| therapy decision factor | Finasteride | Tadalafil |
|---|---|---|
| Drug class | 5-Alpha-Reductase Inhibitor | Pde5 Inhibitor |
| Primary treatment strategy aim | Reduces conversion to dht and can reduce prostate volume over time | Can improve lower urinary tract urinary problems and can also treat erectile dysfunction |
| prostate-volume assessment | Can shrink prostate tissue over months | Does not shrink the prostate |
| Practical timing | Works more slowly than an alpha blocker and is aimed at longer-horizon control in appropriately enlarged prostates | Is considered when urinary urinary problems and erectile function are both part of the therapy decision |
| Blood-pressure context | Usually is not chosen for blood-pressure effects | Vasodilatory effects and interactions, especially with nitrates, are useful to weigh |
| Sexual-function discussion | Reduced libido, erectile or ejaculatory effects can be relevant | Can support erectile function rather than primarily posing an ejaculatory trade-off |
| PSA context | Can lower psa substantially, so psa trends need care team interpretation | Does not have the characteristic psa suppression of 5-alpha-reductase inhibitors |
This comparison is educational. Individual suitability depends on medical history, prostate characteristics, circulatory pressure, other medicines, treatment strategy goals and care team judgment.
When erectile function changes the BPH comparison
Erectile dysfunction can turn an otherwise straightforward BPH medicine choice therapy decision into a multi-goal treatment strategy problem. A medicine that helps erections may be attractive when sexual function is a major priority, but it still has to fit the person's cardiovascular history and other medicines. Nitrate use is a particularly useful to weigh safety issue to discuss with a prescriber.
At the same time, a drug selected for prostate shrinkage or outlet relaxation may address a different part of the disease process. The sensible comparison is therefore not “which pill is best?” but “which treatment strategy goal is currently most useful to weigh, and what trade-offs come with pursuing it?”
Why Finasteride versus Tadalafil is a distinct decision
Finasteride and Tadalafil should not be compared as though they are interchangeable names on the same prescription shelf. Finasteride is best understood as a 5-alpha-reductase inhibitor, while Tadalafil is a PDE5 inhibitor. That difference changes what “success” means, how quickly a response is judged, which adverse effects deserve attention, and what information should be reviewed before switching.
The most useful comparison lens for Finasteride is long-term prostate shrinkage and progression risk versus sexual burden. For Tadalafil, the central lens is combined urinary and erectile-function goals with cardiovascular interaction screening. A patient whose main priority is rapid relief, blood-pressure stability, ejaculation preservation, erectile function, prostate shrinkage or PSA interpretation can therefore reach a different conclusion even when both treatments are reasonable options.
| Decision factor | Finasteride | Tadalafil |
|---|---|---|
| Treatment identity | 5-alpha-reductase inhibitor | PDE5 inhibitor |
| Blood-pressure lens | does not serve as a blood-pressure drug | vasodilation and interaction context matter, especially with nitrates or alpha blockers |
| Sexual-function lens | libido, erectile and ejaculatory effects can affect adherence | can support erectile function while treating urinary symptoms |
| Dosing/timing issue | benefit develops over months rather than days | daily BPH dosing differs from as-needed ED use |
| Best framing | long-term prostate shrinkage and progression risk versus sexual burden | combined urinary and erectile-function goals with cardiovascular interaction screening |
Patient scenarios where the Finasteride–Tadalafil choice changes
If the dominant problem is weak stream with a need for relatively rapid symptom relief, the comparison should emphasize onset and tolerability rather than long-term structural effects. If the dominant concern is a large prostate or progression risk, the relevance of each mechanism changes. If sexual function is the reason for reconsidering treatment, the conversation should separate erectile function from ejaculation because those are not the same outcome.
Blood pressure also changes the decision. For Finasteride, does not serve as a blood-pressure drug. For Tadalafil, vasodilation and interaction context matter, especially with nitrates or alpha blockers. That matters more in someone with antihypertensive therapy, orthostatic symptoms, falls risk or cardiovascular constraints than it does in a patient without those issues.
Dosing details can also decide the practical winner. With Finasteride, benefit develops over months rather than days. With Tadalafil, daily BPH dosing differs from as-needed ED use. Adherence and administration details are not glamorous, but neither is publishing a comparison that ignores the reason a drug fails in real life.
Questions that are specific to choosing between Finasteride and Tadalafil
- Which of my symptoms is Finasteride most likely to improve, and which is Tadalafil most likely to improve?
- How soon should I expect a meaningful response from each option before we judge it?
- Which adverse effect is most likely to make me stop Finasteride, and which is most likely with Tadalafil?
- Does my blood pressure, fall risk or cardiovascular medication list favor one option?
- Do prostate size, PSA interpretation or risk of progression change the value of either drug?
- If the first choice is inadequate, would switching, combining therapy or discussing a procedure make more sense?
Frequently asked questions about Finasteride versus Tadalafil
What is the biggest practical difference between Finasteride and Tadalafil?
Finasteride is a 5-alpha-reductase inhibitor, whereas Tadalafil is a PDE5 inhibitor used daily for BPH. That difference changes the expected response timeline, monitoring priorities and the reasons a clinician might prefer one over the other.
Which works faster for urinary symptoms, Finasteride or Tadalafil?
For Finasteride, the response window usually requires months before its structural effect is fairly judged. For Tadalafil, it is generally assessed over weeks rather than the months required for 5-alpha-reductase inhibition. The comparison should use an appropriate timeline for each mechanism rather than declaring one a failure too early.
How do Finasteride and Tadalafil differ on blood-pressure risk?
With Finasteride, is not a blood-pressure treatment. With Tadalafil, has vasodilator effects and interaction screening is important. Baseline blood pressure, antihypertensive medicines, dizziness and fall history can therefore change which option is easier to tolerate.
Which has the more important sexual-function trade-off?
For Finasteride, libido, erectile and ejaculatory effects can influence adherence. For Tadalafil, can improve erectile function while also treating urinary symptoms. Erectile function, libido and ejaculation should be discussed separately because one treatment can affect these domains differently.
Does Finasteride or Tadalafil shrink an enlarged prostate?
Finasteride: can reduce prostate volume over time. Tadalafil: does not shrink the prostate. This matters when prostate volume or long-term progression risk is central to the treatment goal.
How do Finasteride and Tadalafil affect PSA interpretation?
Finasteride: typically lowers PSA substantially, so interpretation requires an on-treatment baseline. Tadalafil: does not materially suppress PSA. If either treatment changes PSA biology, the clinician should interpret serial values in that treatment context.
Which patient priority most strongly favors Finasteride?
The strongest reason to focus on Finasteride is usually large-prostate strategy, PSA interpretation and delayed onset. That priority should still be weighed against symptom pattern, prostate anatomy, other medicines and adverse-effect tolerance.
Which patient priority most strongly favors Tadalafil?
The strongest reason to focus on Tadalafil is usually erectile-function goals, nitrate contraindication and vasodilator interactions. It becomes more relevant when that issue matters more than the advantages offered by Finasteride.
Can a clinician switch directly from Finasteride to Tadalafil?
Switching depends on why Finasteride is being stopped, how Tadalafil works, interaction risk and whether a washout or overlap is appropriate. The prescriber should give the specific transition plan rather than the patient improvising one.
Could Finasteride and Tadalafil ever be used together?
Combination therapy makes sense only when the mechanisms and safety profile complement each other. Some BPH drug classes are intentionally combined, while pairing two treatments with overlapping effects may add risk without enough benefit.
What if neither Finasteride nor Tadalafil controls the main symptom?
Persistent symptoms should trigger a reassessment of the symptom driver, adherence, treatment duration and anatomy. Urgency, nocturia and weak flow do not always share the same cause, and medication comparisons cannot rule out bladder, sleep, infection or obstruction-related contributors.
When should the Finasteride versus Tadalafil decision become a procedure discussion?
A procedure discussion becomes more relevant when bothersome symptoms persist despite an adequate medical strategy, adverse effects make medication difficult to continue, or objective findings suggest that medication alone is unlikely to meet the treatment goal.
Evidence used on this page
Major treatment claims are anchored to the sources cited on this page, prioritizing official drug labeling, government health agencies, regulators, and professional guidelines.
- Government health source
- Official drug labeling
- Professional guideline
Sources
Sources are provided for general medical context. Drug labeling and professional guidance can change; clinicians should use current prescribing information and guidelines.
Related treatment strategy decisions
Medical note: This page is educational and does not diagnose BPH or tell you to start, stop, or change a prescription. Seek prompt care for urinary retention, fever with urinary urinary problems, severe pain, or substantial blood in the urine.